Promising Clinical Trial Results and Future Prospects Justify Buy Rating for Kura Oncology

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Kura Oncology (KURA – Research Report), retaining the price target of $40.00.

Joseph Pantginis has given his Buy rating due to a combination of factors including the promising clinical trial results of Kura Oncology’s ziftomenib. The updated data from the Phase 1a/1b KOMET-007 trial demonstrated high rates of complete remission and minimal adverse effects when ziftomenib was used in combination with standard chemotherapy treatments for newly diagnosed AML patients.
The safety and efficacy profile of ziftomenib, particularly its potential for combination therapy, is encouraging for its use as a first-line treatment option. Additionally, the anticipation of the Phase 3 KOMET-017 trials, set to begin in the second half of 2025, further supports the positive outlook on Kura Oncology’s stock. These developments suggest a strong potential for ziftomenib to address unmet needs in AML treatment, justifying the Buy rating.

In another report released on June 10, Barclays also maintained a Buy rating on the stock with a $11.00 price target.